SEC Form 4 · accession 0001209191-18-018375
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Aselage
Officer — Chief Executive Officer · Director
Period of report
Mar 7, 2018
Accepted (ET)
Mar 8, 2018 · 9:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 7, 2018 | M | 278 | $6.00 | A | 221,383 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Purchase WarrantsF1 | $6.00 | Mar 7, 2018 | M | 278 | D | Aug 15, 2013 | Aug 15, 2018 | Common Stock | 278 | 0 | D |
Explanation of responses
- F1On August 15, 2013, in connection with a private placement of the Issuer's securities, the Reporting Person acquired 556 shares of the Issuer's common stock, par value $0.0001 per share, at a purchase price of $4.50 per share, and Common Stock Purchase Warrants to purchase up to an aggregate of 278 shares of common stock. The aggregate purchase price paid by the Reporting Person in the transaction was $2,502.